

Indrani Kar, Doctor of Pharmacy Candidate 2013¹, Sharon E. Connor, PharmD¹, Eletta L. Cameron, LSW², and Dawna Woodyear, MD² ¹University of Pittsburgh School of Pharmacy, Pittsburgh, PA ²UPMC Matilda Theiss Health Center, Pittsburgh, PA

INTRODUCTION

Asthma:

- Effects 1:15 Americans (Annual U.S. Prevalence Statistics for Chronic Diseases) • Disproportionately burdens socioeconomically disadvantaged communities
- Is a leading health disparity
- **Underserved patient treatment:**
- Episodic treatment due to lack of following current guidelines

UPMC Matilda Theiss is a FQHC that serves approximately 1,300 primarily underserved patients per year in a medical home model.

OBJECTIVES

- Describe the prevalence of asthma at the health center
- Develop **baseline** knowledge of asthma management

METHODS


- Reviewed medical records for patients with a diagnosis of asthma seen between 5/1/10 and 4/30/11
- Assessed several factors: demographics, spirometry, medication use, asthma severity, peak flow monitor education, etc
- UPMC Total Quality Council approval as QI project

RESULTS

Overview and Demographics

- 1245 patients were seen between 5/1/10 and 4/30/11
- 221 (**17.8%**) have an asthma diagnosis
- Reviewed 218 (17.5%) charts (3 patients deceased)

	Male	Female
Total patients (1245)	28%	72%
Asthma patients (221)	29%	71%



Quality of Care for Asthmatic Patients at an Urban Federally Qualified Health Center (FQHC)

RESULTS continued


Recorded items in electronic medical records

- <u>Severity</u>: Recorded for 9 (4.1%) patients
- Spirometry Scans: Documented for 4 of 13 tested patients
- smoking cessation
- *ER visits for asthma*: 37 patients (17.0%)
- *Education*: For 3 patients on peak flow meter use


Documented pharmacy services

- Smoking cessation and Peak flow meter education
- **Limits**: No link in medical record to asthma action plans

Medication use Asthma Medication Use: 189 out of 218 patients (86.7%)



- Long-term therapy (Total corticosteroid use): 64% (121)
- Short-term therapy (Short acting beta agonist only): 31.2% (59)
- Leukotriene + Corticosteroid + Prednisone: 0%
- Anticholinergic, Leukotriene, and Prednisone monotherapy: 0%



Smoking Cessation: Of 55 smokers (25.2%), 12 (21.8%) were referred for

- SABA only Corticosteroids Corticosteroids+SABA
- Corticosteroid + SABA only
- Corticosteroids+LABA
- Corticosteroid+LABA only
- Corticosteroids+LABA+SABA
- Corticosteroid+LABA+SABA only
- Leukotriene
- Leukotriene+SABA only
- Prednisone

Anticholinergic

<u>Short-term therapy (Total short acting beta agonist use)</u>: 96.8% (183) **Medication Use in ER visits** Patients used SABA and corticosteroids in 67.6% (25 of 37) ER visits SABA + Corticosteroid use Patients used SABA and SABA + no corticosteroid use NO corticosteroids in No SABA + No Corticosteroid 27% (10 of 37) ER visits Corticosteroid + No SABA use LABA – long acting beta agonist

• SABA – short acting beta agonist

Comparison of FQHC results with National statistics National Heart Lung and Blood Institute (NHLBI):

- UPMC Matilda Theiss:

- short acting therapy
- corticosteroid

The NIH 1995 publication, The Role of the Pharmacist in Improving Asthma Care, indicates that "[pharmacists help improve the pharmacologic] management of asthma and overall control by teaching patients about their medications, reviewing with patients how to use their medications, and discussing with patients the importance of using medications as prescribed.]" Pharmacists can assume this role at the health center.

School of Pharmacy



CONCLUSIONS

Lifetime asthma prevalence in the United States: 10.5%

70.7 per 10,000 annual patient ER visits for asthma

Lack of proper documentation for assessment

• Health center prevalence: **17.8%**

<u>1.7 times</u> that of the U.S. population

• Majority of asthma patients are African American: **84.6%**

6.6% increase from general patient population

Approximately 8 times that of asthmatic Caucasians • Health center ER visits: **17.0%**

Minimal documentation of many components for appropriate asthma treatment (ex. Severity)

Medication Use

Lack of severity recorded in chart makes analysis of asthma medication breakdown difficult

31.2% on short acting therapy **ONLY** and may require follow up for appropriate long acting therapy additions

3.2% of patients may require follow up, because patients are not on

27% of asthma patients going to the ER for asthma were **not** on a

Role of the Pharmacist

Quality Improvement Suggestions

Increase incorporation of pharmacists into normal asthma care (education and smoking cessation)

Encourage improved documentation of asthma severity, action plans, and spirometry scans (increased technology use of

electronic medical record) to better assess quality of care **Encourage pharmacists and physicians to increase long term** therapy prescribing and education for asthma patients

Acknowledgements: Matilda Theiss staff and UPMC